Alumis shoots up as its Sotyktu rival aces psoriasis trials

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.

The key to psoriasis innovation? Dispelling the shadow of th...